Biotech By Adam Feuerstein CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions
Adam's Take By Adam Feuerstein Without showing any data, CytoDyn touts treatment for Covid-19 as winner — while its CEO sells stock
Adam's Take By Adam Feuerstein Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last
Adam's Take By Adam Feuerstein Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence
Adam's Take By Adam Feuerstein Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals
Adam's Take By Adam Feuerstein Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’
Adam's Take By Adam Feuerstein Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up
Adam's Take By Adam Feuerstein Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead
Adam's Take By Adam Feuerstein Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too
Adam's Take By Adam Feuerstein Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers
Adam's Take By Adam Feuerstein Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst
Adam's Take By Adam Feuerstein TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin
Adam's Take By Adam Feuerstein Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug
Adam's Take By Adam Feuerstein ‘Pharma doesn’t like fish oil’: Wall Street funds sold Amarin after big win with heart drug
Adam's Take By Adam Feuerstein Investor impatience with Gilead reclamation project sparks acquisition chatter
Adam's Take By Adam Feuerstein If biotech had a Mount Rushmore, whose heads would you chisel in the granite?
Adam's Take By Adam Feuerstein As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking
Adam's Take By Adam Feuerstein Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA
Adam's Take By Adam Feuerstein Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts
Biotech By Adam Feuerstein and Matthew Herper STAT’s guide to the most important, beneficial drugs approved in the past decade
Adam's Take By Adam Feuerstein Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list
Adam's Take By Adam Feuerstein And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!
Adam's Take By Adam Feuerstein Here are the nominees for best biopharma CEO of 2019. Vote for your favorite!
Adam's Take By Adam Feuerstein The good, the bad, and the really, really ugly behind Sarepta’s drug approval
Adam's Take By Adam Feuerstein Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock
Adam's Take By Adam Feuerstein Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval
Adam's Take By Adam Feuerstein A cancer company has misled investors repeatedly about its drug. It’s time for some truth-telling
